Cytokinetics Stock Forecast, Price & News

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cytokinetics stock.
View analyst ratings for Cytokinetics or view top-rated stocks.

Wall Street analysts have given Cytokinetics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cytokinetics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Cytokinetics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Cytokinetics.

Cytokinetics will be holding an earnings conference call on Thursday, August 5th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "7387377".

Cytokinetics, Incorporated (NASDAQ:CYTK) posted its earnings results on Thursday, May, 6th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by $0.07. The biopharmaceutical company had revenue of $6.55 million for the quarter, compared to the consensus estimate of $7.83 million. Cytokinetics had a negative trailing twelve-month return on equity of 213.63% and a negative net margin of 230.55%.
View Cytokinetics' earnings history.

Cytokinetics' stock was trading at $12.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CYTK shares have increased by 141.4% and is now trading at $29.04.
View which stocks have been most impacted by COVID-19.

11 brokerages have issued 12-month target prices for Cytokinetics' stock. Their forecasts range from $16.00 to $54.00. On average, they anticipate Cytokinetics' share price to reach $42.36 in the next twelve months. This suggests a possible upside of 45.9% from the stock's current price.
View analysts' price targets for Cytokinetics or view top-rated stocks among Wall Street analysts.

16 employees have rated Cytokinetics CEO Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among Cytokinetics' employees.

Some companies that are related to Cytokinetics include United Therapeutics (UTHR), Biohaven Pharmaceutical (BHVN), BridgeBio Pharma (BBIO), Mirati Therapeutics (MRTX), HUTCHMED (HCM), Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY), Legend Biotech (LEGN), Perrigo (PRGO), Ascendis Pharma A/S (ASND), I-Mab (IMAB), Sarepta Therapeutics (SRPT), Ultragenyx Pharmaceutical (RARE), Apellis Pharmaceuticals (APLS) and Cassava Sciences (SAVA).
View all of CYTK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Cytokinetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include State of Alaska Department of Revenue (0.07%). Company insiders that own Cytokinetics stock include Bvf Partners L P/Il, Ching Jaw, David Cragg, Fady Ibraham Malik, John T Henderson, L Patrick Gage, Mark A Schlossberg, Robert I Blum, Robert I Blum, Sandford D Smith, Santo J Costa, Value Fund L P Biotechnology and Wendall Wierenga.
View institutional ownership trends for Cytokinetics.

CYTK stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought Cytokinetics stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology.
View insider buying and selling activity for Cytokinetics or or view top insider-buying stocks.

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CYTK stock can currently be purchased for approximately $29.04.

Cytokinetics has a market capitalization of $2.08 billion and generates $55.83 million in revenue each year. The biopharmaceutical company earns $-127,290,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis.

Cytokinetics employs 184 workers across the globe.

Cytokinetics was founded in 1997.

The official website for Cytokinetics is www.cytokinetics.com.

Cytokinetics is headquartered at 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080.

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]